Immunotherapy Publications at Roger Williams Medical Center

Adele R. DecofCancer Center

at Roger Williams Medical Center

Publications

2008

  1. Zhao, T.C., Tseng, A., Yano, N., Tseng, Y. Davol, P.A., Lee, R.J., Lum, L.G., Padbury, J.F. Targeting human CD34+ hematopoietic stem cells with anti-CD45 x anti-myosin light chain bispecific antibody preserves cardiac function in myocardial infarction. J Appl Physiol. 2008 Feb 21; [Epub ahead of print].

2007

  1. Colvin GA, Dooner MS, Dooner GJ, Sanchez-Guijo FM, Demers DA, Abedi M, Ramanathan M, Chung S, Pascual S, Quesenberry PJ. Stem cell continuum: Directed differentiation hotspots. Exp Hematol. 2007 Jan;35(1):96-107.

2006

  1. Lum, L.G., Padbury, J.F., Davol, P.A., Lee, R.J. The Virtual Reality of Stem Cell Transplantation to Repair Injured Myocardium. J Cell. Biochem. 95(5): 869-74, 2005.
  2. Lum,L.G., Davol, P.A.*, Lee,R.J. The New Face of Bispecific Antibodies: Targeting Cancer and Much More. Exp Hematol. 34:1-6, 2006
  3. Reusch, U., Sundaram, M., Davol, P.A.*, Olson, S.D., Davis, J.B., Demel, K., Nissim, J., Rathore, R., Liu, P.Y., Lum, L.G.: Anti-CD3 x anti-EGFR bispecific antibody redirects T cel cytolytic activity to EGFR-positive cancers in vitro and in an animal model. Clin. Cancer. Res. 12:183-190, 2006.
  4. Grabert, R.C., Cousens, L.P.*, Smith, J.A., Oslon, S., Gall, J., Young, W.B., Davol, P.A., Lum, L.G. Human T cells armed with Her2/neu bispecific antibodies divide, are cytotoxic, and secrete cytokines with repeated stimulation. Clin.Cancer Res. 12:569-576, 2006.
  5. Darnowski, J.W., Goulette, F.A., Guan, Y.-J., Chatterjee, D., Yang, Z.-F., Cousens, L.P., Chin, Y.E. Stat3 cleavage by caspases: Impact on full-length Stat3 expression, fragment formation and transcriptional activity. J. Biol. Chem. 281(26): 17707-17717, 2006.
  6. Lee, R.J., Fang, Q., Davol, P.A., Gu, Y., Sievers, R.E., Grabert, R.C., Gall, J.M., Tsang, E., Yee, M.S., Fok, H., Huang, N.F., Padbury, J.F., Larrick, J.W., Lum, L.G. Antibody Targeting of Stem Cells to Infarcted Myocardium. Stem Cells. 2006 Nov 30; [Epub ahead of print].
  7. Frackelton, A.R. Jr., Lu, L., Davol, P.A., Bagdasaryan, R., Hafer, L.J., Sgroi, D.C. p66 Shc and tyrosine-phosphorylated Shc in primary breast cancers identify patients likely to relapse despite tamoxifen therapy. Breast Cancer Res. 2006 Dec 29;8(6):R73 [Epub ahead of print]
  8. Rathore R*, Iannitti D, Soares G, Wanebo H, Maia-Acuna C, Safran H. Hepatic arterial infusion (HAI) of oxaliplatin in advanced hepatocellular cancer (HCC): a phase I study. J Clin Oncol, 2006 ASCO Annual Meeting Proceedings Part I. Vol 24, No. 18S (June 20 Supplement), 2006: 14010
  9. Aliotta JM, Keaney P, Passero M, Dooner MS, Pimentel J, Greer D, Demers D, Foster B, Peterson A, Dooner G, Theise ND, Abedi M, Colvin GA, Quesenberry PJ. Bone marrow production of lung cells: the impact of G-CSF, cardiotoxin, graded doses of irradiation, and subpopulation phenotype. Exp Hematol. 34(2):230-41, 2006.
  10. Lum, L.G., Davol, P.A., Colvin, G.A., Rathore, R., Abedi, M., Palushock, E., Olson, A., Tarro, T., Quesenberry, P. Immune Consolidation After Stem Cell Transplant for Non-Hodgkin's Lymphoma Using Multiple Infusions of Autologous Activated T Cells (ATC) with Anti-CD3 x Anti-CD20 Bispecific Antibody (CD20Bi) to Improve Graft-vs-Lymphoma Effects. ASBMT Meeting, Honolulu, Hawaii, 2006.
  11. Zhao, T.C., Yang, M., Tseng, A., Tseng, Y.-T., Davol, P.A., Lum, L.G., Padbury, J.F. Targeting of human CD34(+) hematopoietic stem cells with myosin light chain preserves cardiac function in chronic infarcted mouse heart. FASEB J 20: 468.6, 2006.
  12. Davol, P.A.*, Gall, J.M., Olson, S.D., Rathore, R., Lum, L.G. Abciximab (ReoPro®), an Antithrombotic Agent, Effectively Redirects the Cytolytic Activity of Activated T Cells (ATC) to Target Acute Myelogenous Leukemia (AML) via Bispecific Antibody (BiAb) Technology. Annual Meeting of the ISEH, 2006.
  13. Lum, L.G., Davol, P.A., Palushock, E.L., Cousens, L.P., Olson, A.L., Winer, E., Rathore, R., Colvin, G.A., Abedi, M., Quesenberry, P.J. CD20-Targeted T Cells for Immune Consolidation After PBSCT for Non-Hodgkin's Lymphoma (NHL) to Improve Graft-vs-Lymphoma Effects (GVL). Annual Meeting of the ISEH, 2006.
  14. Zhao, T.C., Tseng, A., Stabila, J., McGonnigal, B., Yano, N., Tseng, Y.T., Davol, P.A., Lee, R.J., Lum, L.G., Padbury, J.F. The Essential Role of Akt-1 in Hematopoeitic Stem Cells for Preserving Myocardial Function Following Myocardial Infarction. American Heart Association Scientific Sessions, 2006.

2005

  1. Gall JM, Davol PA*, Grabert RC, Deaver M, Lum LG. LG. T Cells Armed with anti-CD3 x anti-CD20 Bispecific Antibody Enhance Killing of CD20+ Malignant B-cells and Bypass Complement-Mediated Rituximab-resistance In Vitro. Exp Hematol. 33(4): 452-459, 2005.
  2. Lum HE, Miller M, Davol PA, Grabert RC, Davis JB, Lum LG. Preclinical Studies Comparing Different Bispecific Antibodies for Redirecting T Cell Cytotoxicity to Extracellular Antigens on Prostate Carcinomas. Anticancer Res. 25 (91a):43-52, 2005.
  3. Lum, L.G. and Davol, P.A. Retargeting T cells and Immune Effector Cells with Bispecific Antibodies. In: Cancer Chemotherapy and Biological Response Modifiers, Annual 22. G. Giaccone, R. Schilsky, P. Sondel (Eds), UK: Elsevier Health Sciences, pp 273-291, 2005.
  4. Lum, L.G., Padbury, J.F., Davol, P.A., Lee, R.J. The Virtual Reality of Stem Cell Transplantation to Repair Injured Myocardium. J Cell. Biochem. 95(5): 869-74, 2005.
  5. Cousens, L.P.*, Goulette, F.A., and Darnowski, J.W. JAK-mediated signaling inhibits Fas Ligand-induced apoptosis independent of de novo protein synthesis. J. Immunol. 174:320-327, 2005.
  6. Reusch, U., Olson, S., Davis, J., Davol, P., Sundarum, M., Liu, L., Lum, L.G. T-Cell Based Cancer Immunotherapy with a Bispecific Antibody Directed at CD3 and EGFR. J Clin Oncol 23(16S):178s, 2005.
  7. Davol, P.A.*, Gall, J.M., Young, W.B., Palushock, E., Rathore, R., Colvin, G.A., Lum, L.G. Clinical and Immune Responses in Breast and Hormone Refractory Prostate Cancer Patients Treated with T Cells Armed with Anti-CD3 x Anti-HER2/neu Bispecific Antibody in a Phase I Clinical Trial. Exp Hematol Suppl 33:7, 2005 (53A).
  8. Lum, L.G., Fang, Q., Davol, P.A., Sievers, R.E., Gall, J.M., Yee, M., Zhao, T., Padbury, J., Larrick, J.W., Lee, R.J. Bispecific Antibody-Enhanced Targeting and Engraftment of Human Hematopoietic Stem Cells is Associated with Preservation of Left Ventricular Function in Rodent Models of Myocardial Infarction. Exp Hematol Suppl 33:7, 2005 (44A).
  9. Quesenberry PJ, Dooner G, Colvin G, Abedi M. Stem cell biology and the plasticity polemic. Exp Hematol. 2005 Apr;33(4):389-94.
  10. Quesenberry PJ, Colvin G, Abedi M. Perspective: fundamental and clinical concepts on stem cell homing and engraftment: a journey to niches and beyond. Exp Hematol. 2005 Jan;33(1):9-19. Review.
  11. Abedi M*, Greer DA, Colvin GA, Demers DA, Dooner MS, Harpel JA, Weier HU, Lambert JF, Quesenberry PJ. Robust conversion of marrow cells to skeletal muscle with formation of marrow-derived muscle cell colonies: a multifactorial process. Exp Hematol. 2004 May;32(5):426-34.
  12. Quesenberry PJ, Dooner G, Dooner M, Abedi. M. Developmental biology: Ignoratio elenchi: red herrings in stem cell research. Science. 2005 May 20;308(5725):1121-2.
  13. Abedi M*, Greer DA, Foster BM, Colvin GA, Harpel JA, Demers DA, Pimentel J, Dooner MS, Quesenberry. Critical variables in the conversion of marrow cells to skeletal muscle. Blood. 2005 Aug 15;106(4):1488-94.
  14. Rathore R*, Chougule P, Wanebo H, Theall K, Ruhl C, Nadeem A, Koness J, Oldenburg N, Kennedy T, Ready N. Phase II Study of Induction Weekly Paclitaxel, Ifosfamide, and Carboplatin (PIC) followed by chemoradiotherapy (CRT) in locally advanced Head and Neck Squamous Cell Cancer (HNSCC): a Brown University Oncology Group study (HN-86). (Abstract 5556) Proc Am Soc Clin Oncol 2005;24.

2004

  1. Ren-Heidenreich L, Davol PA, Kouttab NM, Elfenbein GJ, Lum LG. Redirected T-cell cytotoxicity to EpCAM over-expressing adenocarcinomas by a novel recombinant antibody, E3Bi, in vitro and in an animal model. Cancer, 100:1095-103, 2004.
  2. Darnowski, J.W., Goulette, F.A., Cousens, L.P., Chatterjee, D., and Calabresi, P. Mechanistic and antineoplastic evaluation of Taurolodine in the DU145 model of human prostate cancer. Cancer Chemother. Pharmacol. 54(3):249-258, 2004.
    Davol PA, Lum LG. How Important is HER2/neu Amplification and Expression When Selecting Patients for HER2/neu-Targeted Therapies? Clin. Breast Cancer, 5:70-1, 2004.
  3. Davol PA, Smith JA, Kouttab N, Elfenbein GJ, Lum LG. Anti-CD3 x anti-HER2 bispecific antibody effectively redirects armed T cells to inhibit tumor development and growth in hormone-refractory prostate cancer-bearing severe combined immunodeficient beige mice.
    Clin Prostate Cancer. 2004 Sep;3(2):112-21.
  4. Darnowski, J.W., Goulette, F.A., and Cousens, L.P. Stat3 protein is directly targeted for demolition by cellular caspases. (2004) Proceedings, 94th Annual Meeting of the AACR 44:5642.
  5. Cousens, L.P.*, Goulette, F.A., and Darnowski, J.W. IFNα inhibits FasL-induced apoptosis by a novel mechanism that is independent of new protein synthesis but dependent on JAK activity. (2004) Proceedings, 94th Annual Meeting of the AACR 44:5642.
  6. Gall, J.M., Grabert, R.C., Deavers, M., Davol, P.A., and Lum, L.G. Targeting CD20+ Rituxan Resistant B-Cells with Anti-CD3 Activated T cells (ATC) Armed with anti-CD3 x anti-CD20 (CD20Bi). Annual Meeting of the International Society for Experimental Hematology, 32(7S):19A, 2004.
  7. Lum, L.G., Davol, P.A., Sievers, R.E., Grabert, R.C., Gall, J.M.,Yee, M.S., Maizel. A.L., Larrick, J.W., Lee, R.J. Bispecific Antibodies Directed at Injury-Specific Adhesion Molecules Enhance Homing of Human Cells to Myocardial Infarctions in a Xenogeneic Rat Model. Annual Meeting of the International Society for Experimental Hematology, 32(7S):22A, 2004.
  8. Lee, R.J., Davol, P.A., Fang, Q., Sievers, R., Yee, M., Grabert, R.C., Larrick, J., Lum, L.G. Targeting of Human Stem Cells to Myocardial Infarctions in a Xenogeneic Rat Model. Annual Meeting of the Biomedical Engineering Society, October 14, 2004.
  9. Olson, S., Davol, P.A., Lum, L.G. Enhancing Anti-Tumor Activity Against Glioblastoma and Neuroblastoma by Retargeting T Cells with OKT3 x Anti-EGFR. J Immunotherapy 27(6):s4, 2004.
  10. Davol, P.A., Gall, J.M., Grabert, R.C., Young, W.B., Cummings, F.J., Rathore, R., Colvin, G.A., Elfenbein, G.J., Lum, L.G. Infusions of T Cells Armed with anti-CD-3 x anti-Her2/neu Bispecific Antibody Modulate In Vivo Patient Immune Responses in Phase I Clinical Trials for Breast and Hormone Refractory Prostate Cancers. Blood 104(11):379a, 2004.
  11. Lum, L.G., Davol, P.A., Sievers, R.E., Grabert, R.C., Fang, Q, Gall, J.M., Yee, M.S., Larrick, J.W., Lee, R.J. Human Stem Cells Armed with Bispecific Antibodies Home to Injury-Specific Molecules in Myocardial Infarcts in Nude Rats. Blood 104(11):736a, 2004.
  12. Rathore R*, Chougule P, Wanebo H, Nadeem A, Radie-Keane K, Sikov W, Nigri P, Kennedy T, Ready N. Phase I/II study of induction weekly Paclitaxel, Ifosfamide and Carboplatin (PIC) followed by chemoradiotherapy (CRT) in advanced head and neck squamous cell cancers (HN-SCC). (Abstract 5602) Proc Am Soc Clin Oncol 2004;23:511.
  13. Chauhan B, Wanebo H, Rathore R, Chougule P, Kennedy T, Ready N. Phase I/II study of Carboplatin with dose dense weekly Ifosfamide and Docetaxel in recurrent or metastatic head and neck squamous cell cancers (HN-SCC). (Abstract 5601) Proc Am Soc Clin Oncol 2004;23:511.
  14. Safran H, DiPetrillo T, Steinhoff M, Rathore R, Chak B, Choy H. The HER-2/neu gene is an important target in adenocarcinoma of the esophagus: A phase I/II trial of trastuzumab, paclitaxel, cisplatin and radiation. (Abstract 24) Presented at 2004 ASCO GI Cancers Symposium.
  • 825 Chalkstone Avenue, Providence, Rhode Island 02908
  • 401-456-2000

© 2011 CharterCARE Health Partners